@article{RN499,
   author = {Jeannetot, D. and de Ridder, M. and Mosseveld, M. and Pedersen, L. and Lapi, F. and Marconi, E. and Tan, E. H. and Delmestri, A. and Prieto-Alhambra, D. and Van Der Deijl, M. and Brusselle, G. and Verhamme, K.},
   title = {Treatment choice for adult patients with moderate-to-severe asthma: the TAILOR study},
   journal = {ERJ Open Res},
   volume = {11},
   number = {3},
   note = {2312-0541
Jeannetot, Daniel
Orcid: 0000-0001-8797-0883
de Ridder, Maria
Mosseveld, Mees
Orcid: 0000-0001-9301-8565
Pedersen, Lars
Lapi, Francesco
Marconi, Ettore
Tan, Eng Hooi
Orcid: 0000-0003-4470-2736
Delmestri, Antonella
Orcid: 0000-0003-0388-3403
Prieto-Alhambra, Daniel
Van Der Deijl, Marielle
Brusselle, Guy
Orcid: 0000-0001-7021-8505
Verhamme, Katia
Orcid: 0000-0001-8162-4904
Journal Article
England
2025/07/01
ERJ Open Res. 2025 Jun 30;11(3):00869-2024. doi: 10.1183/23120541.00869-2024. eCollection 2025 May.},
   abstract = {BACKGROUND: In patients with uncontrolled asthma treated with medium dose inhaled corticosteroid/long-acting β(2)-agonist (ICS/LABA), the Global Initiative for Asthma (GINA) recommends to increase to high-dose ICS/LABA or to start therapy consisting of medium-dose ICS/LABA+LAMA (long-acting muscarinic antagonist). Adding LAMA on top of high-dose ICS/LABA is not recommended for Step 4 asthma patients, yet it is used in the real world. Patient characteristics influencing treatment step-up are unknown. The objectives of the present study were to identify determinants of step-up option (high-dose ICS/LABA, medium-dose ICS/LABA+LAMA, high-dose ICS/LABA+LAMA) in patients with moderate to severe asthma. METHODS: A retrospective cohort study using three primary care databases (IPCI, HSD, CPRD GOLD) and one prescription database (Aarhus) included asthma patients with step-up after ≥3 months use of medium-dose ICS/LABA, from January 2010 to April 2020. Characteristics of patients were described, and determinants of choice for medium-dose ICS/LABA+LAMA or high dose ICS/LABA were investigated. RESULTS: 492 639 adults with asthma and ≥1 year of database history were identified and 25 558 were eligible for analysis. 6126 patients stepped-up to medium-dose ICS/LABA+LAMA and 18 947 patients stepped-up to high-dose ICS/LABA. Determinants for step-up to medium-dose ICS/LABA+LAMA were higher age and presence of COPD whereas history of atopy lowered this choice. Other covariates were differentially associated with specific treatment step-up depending on the databases. CONCLUSION: In uncontrolled asthma patients on medium-dose ICS/LABA, treatment step-up with add-on LAMA was more likely than step-up to high-dose ICS/LABA in older patients, current smokers, with a history of asthma exacerbations and concomitant diagnosis of COPD.},
   ISSN = {2312-0541 (Print)
2312-0541},
   DOI = {10.1183/23120541.00869-2024},
   year = {2025},
   type = {Journal Article}
}

{"_id":"PqErSN2zjMFxT7rfC","bibbaseid":"jeannetot-deridder-mosseveld-pedersen-lapi-marconi-tan-delmestri-etal-treatmentchoiceforadultpatientswithmoderatetosevereasthmathetailorstudy-2025","author_short":["Jeannetot, D.","de Ridder, M.","Mosseveld, M.","Pedersen, L.","Lapi, F.","Marconi, E.","Tan, E. H.","Delmestri, A.","Prieto-Alhambra, D.","Van Der Deijl, M.","Brusselle, G.","Verhamme, K."],"bibdata":{"bibtype":"article","type":"Journal Article","author":[{"propositions":[],"lastnames":["Jeannetot"],"firstnames":["D."],"suffixes":[]},{"propositions":["de"],"lastnames":["Ridder"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Mosseveld"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Pedersen"],"firstnames":["L."],"suffixes":[]},{"propositions":[],"lastnames":["Lapi"],"firstnames":["F."],"suffixes":[]},{"propositions":[],"lastnames":["Marconi"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Tan"],"firstnames":["E.","H."],"suffixes":[]},{"propositions":[],"lastnames":["Delmestri"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Prieto-Alhambra"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Van","Der","Deijl"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Brusselle"],"firstnames":["G."],"suffixes":[]},{"propositions":[],"lastnames":["Verhamme"],"firstnames":["K."],"suffixes":[]}],"title":"Treatment choice for adult patients with moderate-to-severe asthma: the TAILOR study","journal":"ERJ Open Res","volume":"11","number":"3","note":"2312-0541 Jeannetot, Daniel Orcid: 0000-0001-8797-0883 de Ridder, Maria Mosseveld, Mees Orcid: 0000-0001-9301-8565 Pedersen, Lars Lapi, Francesco Marconi, Ettore Tan, Eng Hooi Orcid: 0000-0003-4470-2736 Delmestri, Antonella Orcid: 0000-0003-0388-3403 Prieto-Alhambra, Daniel Van Der Deijl, Marielle Brusselle, Guy Orcid: 0000-0001-7021-8505 Verhamme, Katia Orcid: 0000-0001-8162-4904 Journal Article England 2025/07/01 ERJ Open Res. 2025 Jun 30;11(3):00869-2024. doi: 10.1183/23120541.00869-2024. eCollection 2025 May.","abstract":"BACKGROUND: In patients with uncontrolled asthma treated with medium dose inhaled corticosteroid/long-acting β(2)-agonist (ICS/LABA), the Global Initiative for Asthma (GINA) recommends to increase to high-dose ICS/LABA or to start therapy consisting of medium-dose ICS/LABA+LAMA (long-acting muscarinic antagonist). Adding LAMA on top of high-dose ICS/LABA is not recommended for Step 4 asthma patients, yet it is used in the real world. Patient characteristics influencing treatment step-up are unknown. The objectives of the present study were to identify determinants of step-up option (high-dose ICS/LABA, medium-dose ICS/LABA+LAMA, high-dose ICS/LABA+LAMA) in patients with moderate to severe asthma. METHODS: A retrospective cohort study using three primary care databases (IPCI, HSD, CPRD GOLD) and one prescription database (Aarhus) included asthma patients with step-up after ≥3 months use of medium-dose ICS/LABA, from January 2010 to April 2020. Characteristics of patients were described, and determinants of choice for medium-dose ICS/LABA+LAMA or high dose ICS/LABA were investigated. RESULTS: 492 639 adults with asthma and ≥1 year of database history were identified and 25 558 were eligible for analysis. 6126 patients stepped-up to medium-dose ICS/LABA+LAMA and 18 947 patients stepped-up to high-dose ICS/LABA. Determinants for step-up to medium-dose ICS/LABA+LAMA were higher age and presence of COPD whereas history of atopy lowered this choice. Other covariates were differentially associated with specific treatment step-up depending on the databases. CONCLUSION: In uncontrolled asthma patients on medium-dose ICS/LABA, treatment step-up with add-on LAMA was more likely than step-up to high-dose ICS/LABA in older patients, current smokers, with a history of asthma exacerbations and concomitant diagnosis of COPD.","issn":"2312-0541 (Print) 2312-0541","doi":"10.1183/23120541.00869-2024","year":"2025","bibtex":"@article{RN499,\r\n author = {Jeannetot, D. and de Ridder, M. and Mosseveld, M. and Pedersen, L. and Lapi, F. and Marconi, E. and Tan, E. H. and Delmestri, A. and Prieto-Alhambra, D. and Van Der Deijl, M. and Brusselle, G. and Verhamme, K.},\r\n title = {Treatment choice for adult patients with moderate-to-severe asthma: the TAILOR study},\r\n journal = {ERJ Open Res},\r\n volume = {11},\r\n number = {3},\r\n note = {2312-0541\r\nJeannetot, Daniel\r\nOrcid: 0000-0001-8797-0883\r\nde Ridder, Maria\r\nMosseveld, Mees\r\nOrcid: 0000-0001-9301-8565\r\nPedersen, Lars\r\nLapi, Francesco\r\nMarconi, Ettore\r\nTan, Eng Hooi\r\nOrcid: 0000-0003-4470-2736\r\nDelmestri, Antonella\r\nOrcid: 0000-0003-0388-3403\r\nPrieto-Alhambra, Daniel\r\nVan Der Deijl, Marielle\r\nBrusselle, Guy\r\nOrcid: 0000-0001-7021-8505\r\nVerhamme, Katia\r\nOrcid: 0000-0001-8162-4904\r\nJournal Article\r\nEngland\r\n2025/07/01\r\nERJ Open Res. 2025 Jun 30;11(3):00869-2024. doi: 10.1183/23120541.00869-2024. eCollection 2025 May.},\r\n abstract = {BACKGROUND: In patients with uncontrolled asthma treated with medium dose inhaled corticosteroid/long-acting β(2)-agonist (ICS/LABA), the Global Initiative for Asthma (GINA) recommends to increase to high-dose ICS/LABA or to start therapy consisting of medium-dose ICS/LABA+LAMA (long-acting muscarinic antagonist). Adding LAMA on top of high-dose ICS/LABA is not recommended for Step 4 asthma patients, yet it is used in the real world. Patient characteristics influencing treatment step-up are unknown. The objectives of the present study were to identify determinants of step-up option (high-dose ICS/LABA, medium-dose ICS/LABA+LAMA, high-dose ICS/LABA+LAMA) in patients with moderate to severe asthma. METHODS: A retrospective cohort study using three primary care databases (IPCI, HSD, CPRD GOLD) and one prescription database (Aarhus) included asthma patients with step-up after ≥3 months use of medium-dose ICS/LABA, from January 2010 to April 2020. Characteristics of patients were described, and determinants of choice for medium-dose ICS/LABA+LAMA or high dose ICS/LABA were investigated. RESULTS: 492 639 adults with asthma and ≥1 year of database history were identified and 25 558 were eligible for analysis. 6126 patients stepped-up to medium-dose ICS/LABA+LAMA and 18 947 patients stepped-up to high-dose ICS/LABA. Determinants for step-up to medium-dose ICS/LABA+LAMA were higher age and presence of COPD whereas history of atopy lowered this choice. Other covariates were differentially associated with specific treatment step-up depending on the databases. CONCLUSION: In uncontrolled asthma patients on medium-dose ICS/LABA, treatment step-up with add-on LAMA was more likely than step-up to high-dose ICS/LABA in older patients, current smokers, with a history of asthma exacerbations and concomitant diagnosis of COPD.},\r\n ISSN = {2312-0541 (Print)\r\n2312-0541},\r\n DOI = {10.1183/23120541.00869-2024},\r\n year = {2025},\r\n type = {Journal Article}\r\n}\r\n\r\n","author_short":["Jeannetot, D.","de Ridder, M.","Mosseveld, M.","Pedersen, L.","Lapi, F.","Marconi, E.","Tan, E. H.","Delmestri, A.","Prieto-Alhambra, D.","Van Der Deijl, M.","Brusselle, G.","Verhamme, K."],"key":"RN499","id":"RN499","bibbaseid":"jeannetot-deridder-mosseveld-pedersen-lapi-marconi-tan-delmestri-etal-treatmentchoiceforadultpatientswithmoderatetosevereasthmathetailorstudy-2025","role":"author","urls":{},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/network/files/qwipow2DJsAxqNp83","dataSources":["PcZMFHooKwpboi2he","jZMXEeHTfokmisJDv"],"keywords":[],"search_terms":["treatment","choice","adult","patients","moderate","severe","asthma","tailor","study","jeannetot","de ridder","mosseveld","pedersen","lapi","marconi","tan","delmestri","prieto-alhambra","van der deijl","brusselle","verhamme"],"title":"Treatment choice for adult patients with moderate-to-severe asthma: the TAILOR study","year":2025}